Constipation Clinical Trial
Official title:
Effect of Inulin-type Fructans on Constipated Children. Pilot Study.
The main objective of this Pilot study was to assess the beneficial effects of a daily
supplementation with Orafti inulin‐type fructans in 2‐5 year old constipated children The
study is primary aimed to develop a feasibility study to assess the beneficial effect of
inulin‐type fructans in the described population with regard to the adequate criteria for a
larger trial. Secondary objectives are to obtain data about the feasibility of the protocol
(as pilot study). To obtain data useful to perform sample size calculations for a big study
designed specifically to investigate the beneficial effect of inulin‐type fructans in the
treatment of constipated children.
Study design and subjects: Double‐blind, randomized, placebo‐controlled parallel group
trial; where 2‐5 year‐old constipated children received inulin‐type fructans or the same
amount of placebo (maltodextrin) during 6 weeks. The study protocol was approved by the
local Ethical Committees.
Outcomes: primary outcome was stool consistency. Secondary outcomes were: stool frequency,
gastrointestinal symptoms (abdominal pain and pain during defecation), additional medication
required (yes/no), and colonic transit time. Stool samples at baseline, end of intervention
and after follow‐up were obtained in order to be analysed to know about the microbiota.
Dietary intake was also recorded at baseline, end of intervention and after follow-up.
Principal subject inclusion criteria: Subjects were recruited if fulfil the Rome III
constipation criteria (Mainly hard stools plus stool retention, or pain, or low frequency).
Principal subject exclusion criteria: Age under 2 or over 5 years, diapers use, use of
laxative during the study and 2 weeks before, use of pre‐ probiotics or antibiotics during
the study and 4 weeks before, organic causes of defecation disorders, other metabolic or
renal abnormalities or mental retardation, no parent's command of any local language.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
| Recruiting |
NCT06292949 -
Clinical Study of Resistant Starch in Improving Constipation
|
N/A | |
| Recruiting |
NCT04132661 -
MRI Assessment of Mode of Action of Bisacodyl, Single Dose
|
Phase 4 | |
| Terminated |
NCT02839889 -
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
|
Phase 4 | |
| Completed |
NCT02726295 -
The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study
|
Phase 4 | |
| Recruiting |
NCT02255747 -
Anal Dilatation for Infants and Children With Constipation
|
N/A | |
| Completed |
NCT02246647 -
Biomarkers for Intestinal Permeability in Patients With Constipation
|
||
| Completed |
NCT01566409 -
Maintenance Treatment for Children With Constipation
|
N/A | |
| Completed |
NCT01695915 -
Diurnal Variation in Rectal Diameter
|
N/A | |
| Completed |
NCT02658201 -
Ultrafast MRI Imaging to Exclude Constipation
|
N/A | |
| Completed |
NCT01710579 -
Normal Values in Ano-rectal 3D High Resolution Manometry
|
N/A | |
| Completed |
NCT01438567 -
A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
|
Phase 3 | |
| Completed |
NCT01411501 -
Efficacy and Safety of Acupuncture for Functional Constipation
|
Phase 3 | |
| Completed |
NCT01474499 -
A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation
|
Phase 3 | |
| Completed |
NCT01170039 -
The Effectiveness of Lubiprostone in Constipated Diabetics
|
Phase 4 | |
| Completed |
NCT00931853 -
Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC).
|
Phase 3 | |
| Active, not recruiting |
NCT02442115 -
Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
|
||
| Terminated |
NCT01003249 -
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
|
Phase 4 | |
| Completed |
NCT00994851 -
Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.
|
Phase 3 | |
| Completed |
NCT01607060 -
Impact of Laxative Therapy With Lactulose in the Evolution of Organ Dysfunction in Critically Ill Patients.
|
Phase 3 |